Vlidaplit 100 Tablet contains Vildagliptin 100mg, a clinically proven oral anti-diabetic agent that helps regulate blood glucose levels in type-2 diabetes mellitus. It works by inhibiting DPP-4, thereby increasing incretin hormones, enhancing insulin secretion, and reducing glucagon release in a glucose-dependent manner.
This mechanism ensures effective control of fasting and postprandial blood sugar, improving overall glycemic stability. The tablet offers a convenient once-daily oral dosage, supporting patient adherence and consistent therapeutic outcomes in long-term diabetes management.
Vlidaplit 100 Tablet is widely used by endocrinologists, diabetologists, and general physicians for patients who require DPP-4 inhibitor therapy, either as monotherapy or in combination with other oral anti-diabetic drugs.
Adding Vlidaplit 100 Tablet to your diabetes and metabolic-care portfolio strengthens your product range, creating opportunities in retail pharmacy distribution, hospital supply, institutional procurement, export markets, and third-party manufacturing. Its high clinical relevance ensures steady demand and profitable performance for pharmaceutical distributors.